| Aspect | Key findings (1-3 bullets) | Evidence & quantitative details | Key sources (first author year, journal) | URL |
|---|---|---|---|---|
| Definition / target verification | • Human **EDEM1** corresponds to **ER degradation-enhancing alpha-mannosidase-like protein 1** (UniProt **Q92611**).<br>• Member of **glycosyl hydrolase family 47** / mannosidase-like ER quality-control proteins.<br>• Functions in ER glycoprotein quality control and ER-associated degradation (ERAD). | Experimental/review context consistently places EDEM1 in mammalian ERAD as a GH47 mannosidase-like factor acting on misfolded glycoproteins rather than an unrelated protein; family assignment and ERAD role are concordant across mechanistic studies and reviews (pqac-00000001, pqac-00000004, pqac-00000007). | Shenkman 2018, *Communications Biology*; Chiritoiu 2020, *IJMS* | https://doi.org/10.1038/s42003-018-0174-8 ; https://doi.org/10.3390/ijms21103468 |
| Primary molecular function / enzymatic activity | • **Bona fide mannosidase activity** demonstrated in vitro for human EDEM1.<br>• Activity is **much stronger on unfolded/denatured glycoproteins** than on free glycans or native glycoproteins.<br>• Catalytic residue **E488** is required for activity and ERAD support. | EDEM1 shows only modest trimming on free N-glycans/native glycoproteins but **>3-fold higher activity on denatured glycoproteins**; trims oligomannose species from **M8 toward M5**, contributing especially to **M8→M7** and **M6→M5** steps. **E488Q** mutant loses mannosidase activity and acts dominant-negatively on ERAD substrate degradation (pqac-00000000, pqac-00000003, pqac-00000004, pqac-00000005). | Shenkman 2018, *Communications Biology*; Lamriben 2018, *JBC* | https://doi.org/10.1038/s42003-018-0174-8 ; https://doi.org/10.1074/jbc.ra118.004183 |
| Substrate specificity / recognition mode | • Prefers **misfolded or unfolded glycoproteins** rather than properly folded substrates.<br>• Recognition is not purely glycan-based: EDEM1 also uses **protein–protein interactions** and redox-sensitive contacts.<br>• N- and C-terminal **intrinsically disordered regions (IDRs)** contribute to substrate/partner binding. | EDEM1 mannosidase activity rises sharply when glycoprotein substrate is denatured; knockdown reduces OS-9 association of ERAD substrate **H2a to ~20% of control** (~80% reduction). The mannosidase-like domain can bind ERAD clients in a **thiol/redox-sensitive** manner; IDRs are required for interaction with ERAD factor **ERdj5** and for efficient client binding/degradation (pqac-00000000, pqac-00000004, pqac-00000007). | Shenkman 2018, *Communications Biology*; Lamriben 2018, *JBC*; Chiritoiu 2020, *IJMS* | https://doi.org/10.1038/s42003-018-0174-8 ; https://doi.org/10.1074/jbc.ra118.004183 ; https://doi.org/10.3390/ijms21103468 |
| Localization / topology | • EDEM1 is an **ER-resident** quality-control factor.<br>• 2024 work indicates **both soluble and membrane-associated / transmembrane forms** can exist.<br>• Membrane-associated form appears more aggregation-prone and can be selectively handled by some turnover factors. | Katsuki et al. report EDEM1 has **five N-glycans**, undergoes **post-translational signal-sequence cleavage**, and yields **soluble and type II transmembrane forms**; alkaline extraction/fractionation showed substantial membrane association (**S/P ~20/80 or 35/65** depending on condition/cofactors). Figure-based evidence shows ER localization under KIF and aggresome relocalization with proteasome inhibition (pqac-00000008, pqac-00000009, pqac-00000015). | Katsuki 2024, *Genes to Cells*; Chiritoiu 2020, *IJMS* | https://doi.org/10.1111/gtc.13117 ; https://doi.org/10.3390/ijms21103468 |
| Pathway role in ER quality control / ERAD | • EDEM1 helps extract terminally misfolded proteins from the **calnexin cycle** and route them to **HRD1–SEL1L ERAD**.<br>• Associates with ERAD lectins/chaperones including **OS-9, XTP3-B, SEL1L, HRD1, ERdj proteins**.<br>• Can contribute to degradation of some **nonglycosylated** misfolded proteins via protein-based recognition. | Co-complexing with **SEL1L, OS-9, XTP3-B, HRD1, PSMC6, ERdj4/5, calnexin, UGGTs** supports placement in luminal ERAD handoff complexes; catalytic and noncatalytic substrate engagement both contribute to routing. Earlier work also supports shared ERAD machinery for glycosylated and nonglycosylated substrates involving EDEM1 (pqac-00000001, pqac-00000002, pqac-00000007). | Chiritoiu 2020, *IJMS*; Christianson 2023, *Nat Rev Mol Cell Biol*; Shenkman 2013, *JBC* | https://doi.org/10.3390/ijms21103468 ; https://doi.org/10.1038/s41580-023-00633-8 ; https://doi.org/10.1074/jbc.m112.438275 |
| Regulation by ER stress / UPR | • **UPR/ER stress induces EDEM1 expression**.<br>• EDEM1 itself is also tightly controlled post-translationally by degradation pathways.<br>• Perturbing ERAD can modestly raise EDEM1 and BiP levels. | Katsuki 2024 states EDEM1 gene expression is **upregulated by ER stress/UPR**; protein turnover is fast (**half-life ~3 h** by CHX chase). Chiritoiu 2020 found **kifunensine** and **SEL1L depletion** increase EDEM1 stability/abundance, with mild **BiP** upregulation during ERAD perturbation (pqac-00000008, pqac-00000011, pqac-00000012, pqac-00000015). | Katsuki 2024, *Genes to Cells*; Chiritoiu 2020, *IJMS* | https://doi.org/10.1111/gtc.13117 ; https://doi.org/10.3390/ijms21103468 |
| Turnover and autoregulation (2024 emphasis) | • EDEM1 is itself degraded by **ERAD and autophagy**.<br>• **SEL1L/Hrd1, YOD1, XTP3B, ERdj3, VIMP, BAG6, JB12** participate in EDEM1 turnover.<br>• **OS9 binds EDEM1** but did not measurably drive its turnover in the 2024 study. | CHX chase: **~3 h half-life**. **KIF** or **MG132** stabilizes EDEM1. **SEL1L knockout** upregulates EDEM1; **Hrd1 C329S** impairs turnover; **XTP3B** overexpression lowers EDEM1 in a **KIF-sensitive** manner; inactive **YOD1 C160S** increases ubiquitinated, detergent-insoluble EDEM1. Statistical analyses reported from **3–4 independent experiments**, with significance including **P < 0.05** and **P < 0.01** (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000011, pqac-00000015). | Katsuki 2024, *Genes to Cells* | https://doi.org/10.1111/gtc.13117 |
| Backup lysosomal disposal / ER-phagy-ERLAD | • When ERAD is impaired, EDEM1-linked pathways connect to **ER-phagy / ER-to-lysosome-associated degradation (ERLAD)** as a failsafe.<br>• **FAM134B** and **LC3 lipidation** are required for rerouting canonical ERAD clients.<br>• Supports a model in which EDEM1 loss/inhibition does not fully block disposal but shifts it to lysosomes. | Fasana 2024: **EDEM1 silencing** redirects **NHK** to degradative endolysosomes; pharmacologic ERAD inhibition (**KIF**, **PS341**) reroutes **NHK** and **BACE457Δ** to **LAMP1+** compartments. Delivery requires **FAM134B** and its **LIR motif**; **ATG7** deletion blocks delivery, whereas **ATG13** deletion does not. Example pulse-chase retentions at 120 min under ERAD inhibition: NHK mock **37–49%** vs **KIF 53–80%**, **PS341 52–73%**, and even higher with lysosome block; BACE457Δ mock **36–54%** vs **KIF 72–75%**, **PS341 70–84%**. LysoQuant analyses used multiple cell counts and **N=2–3** experiments; several comparisons reached ******P < 0.0001** (pqac-00000020, pqac-00000021, pqac-00000022, pqac-00000023, pqac-00000025). | Fasana 2024, *EMBO Reports*; Chiritoiu 2020, *IJMS* | https://doi.org/10.1038/s44319-024-00165-y ; https://doi.org/10.3390/ijms21103468 |
| Real-world / disease-linked applications | • EDEM1 level or activity is being used mainly as a **proteostasis/ER stress marker** in cell biology and disease models.<br>• Manipulating EDEM1 can alter fate of disease-relevant clients such as **APP** and viral proteins.<br>• No approved EDEM1-targeted therapy was identified; current use is mechanistic and preclinical. | In human cell models, EDEM1 overproduction reduces **APP** levels and decreases **Aβ40/Aβ42** secretion, supporting relevance to Alzheimer-related proteostasis; recent literature also cites EDEM1 in viral exploitation and stress-pathway studies, but translation remains preclinical. The strongest current “implementation” is use of EDEM1 as a pathway node/marker in ERAD- and UPR-focused experiments rather than a clinical biomarker or drug target (pqac-00000001, pqac-00000008). | Nowakowska-Gołacka 2021, *IJMS*; Katsuki 2024, *Genes to Cells* | https://doi.org/10.3390/ijms23010117 ; https://doi.org/10.1111/gtc.13117 |


*Table: This table summarizes core evidence for the identity, function, localization, regulation, pathway role, and applications of human EDEM1 (UniProt Q92611). It emphasizes the most informative mechanistic studies, especially Katsuki 2024 on EDEM1 turnover and Fasana 2024 on ERLAD compensation when ERAD is impaired.*